People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TFF Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $49.4M | $9.2M | 2018 |
ROBERT S. MILLS, JR. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ROBERT S. MILLS, JR. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| CATHERINE S. LEE | 1 | 2 |
| THOMAS S. KING | 1 | 1 |
| STEPHEN S. ROCAMBOLI | 1 | 1 |
| HARLAN S. WEISMAN | 1 | 1 |
| ZAMANEH S. MIKHAK | 1 | 1 |
| KIRK S. COLEMAN | 1 | 1 |
| MICHAEL S. PATANE | 1 | 1 |
| RANDY S. THURMAN | 1 | 1 |
| MALCOLM S. FAIRBAIRN | 1 | 1 |
| BRIAN S. WINDSOR | 1 | 1 |
| AARON S. FLETCHER | 1 | 1 |
| BRANDI S. ROBERTS | 1 | 1 |
| GLENN S. MATTES | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.